Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Blood

Volumn 119, Issue 26, 2012, Pages 6226-6233

  Klinger, Matthias ^a   Brandl, Christian ^a   Zugmaier, Gerhard ^a   Hijazi, Youssef ^a   Bargou, Ralf C ^b   Topp, Max S ^b   Gökbuget, Nicola ^c   Neumann, Svenja ^d   Goebeler, Mariele ^b   Viardot, Andreas ^e   Stelljes, Matthias ^f   Brüggemann, Monika ^d   Hoelzer, Dieter ^c   Degenhard, Evelyn ^a   Nagorsen, Dirk ^a   Baeuerle, Patrick A ^a   Wolf, Andreas ^a   Kufer, Peter ^a  

^a Amgen Research GmbH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; CD19 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUMP; T LYMPHOCYTE;

EID: 84863522243     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-400515     Document Type: Article

References (31)

1. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-1146. (Pubitemid 46718398)
2. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011;186(3):1325-1331.
3. Casalegno-Garduño R, Schmitt A, Schmitt M. Clinical peptide vaccination trials for leukemia patients. Expert Rev Vaccines. 2011;10(6):785-799.
4. Klein O, Schmidt C, Knights A, Davis ID, Chen W, Cebon J. Melanoma vaccines: developments over the past 10 years. Expert Rev Vaccines. 2011;10(6):853-873.
5. Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy. 2010;2(3):367-379.
6. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958-6962.
7. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666-675. (Pubitemid 37328821)
8. Hershkovitz L, Schachter J, Treves AJ, Besser MJ. Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol. 2010;2010:260267.
9. Copier J, Bodman-Smith M, Dalgleish A. Current status and future applications of cellular therapies for cancer. Immunotherapy. 2011;3(4):507-516.
10. Willimsky G, Blankenstein T. The adaptive immune response to sporadic cancer. Immunol Rev. 2007;220:102-112. (Pubitemid 350045578)
11. Zimmerman M, Hu X, Liu K. Experimental metastasis and CTL adoptive transfer immunotherapy mouse model. J Vis Exp. 2010;(45):e2077.
12. Biagi E, Marin V, Giordano Attianese GM, Dander E, D'Amico G, Biondi A. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica. 2007;92(3):381-388. (Pubitemid 350143548)
13. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
14. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255-1260.
15. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974- 977.
16. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
17. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100(6):690-697. (Pubitemid 34832980)
18. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115(1):98-104. (Pubitemid 40559673)
19. Schlereth B, Quadt C, Dreier T, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother. 2006;55(5):503-514.
20. Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43(8):1129-1143. (Pubitemid 43063166)
21. Lutterbuese R, Raum T, Kischel R, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 2009;32(4):341-352.
22. Raff T, Gökbuget N, Lüschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3):910-915. (Pubitemid 46220634)
23. Kikuchi M, Tanaka J, Kondo T, et al. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Int J Hematol. 2010;92(3):481-489.
24. Cazzaniga G, Valsecchi MG, Gaipa G, Conter V, Biondi A. Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. Br J Haematol. 2011;155(1):45-52.
25. Löffler A, Kufer P, Lutterbüse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098-2103. (Pubitemid 30151651)
26. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84(5):1415-1420. (Pubitemid 24273007)
27. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. (Pubitemid 39506617)
28. Haas C, Krinner E, Brischwein K, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 2009;214(6):441-453.
29. Berard M, Tough DF. Qualitative differences between naive and memory T cells. Immunology. 2002;106(2):127-138. (Pubitemid 34621821)
30. Farber DL. Biochemical signaling pathways for memory T cell recall. Semin Immunol. 2009;21(2):84-91.
31. Brischwein K, Parr L, Pflanz S, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother. 2007;30(8):798-807. (Pubitemid 350295358)